A genome-wide association study of contralateral breast cancer in the Women’s Environmental Cancer and Radiation Epidemiology Study

[1] Chen Y(1999)Epidemiology of contralateral breast cancer Cancer Epidemiol Biomark Prev 8 855-861

[2] Thompson W(2010)Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2 J Clin Oncol 28 2404-2410

[3] Semenciw R(2023)The impact of coding germline variants on contralateral breast cancer risk and survival Am J Hum Genet 110 475-486

[4] Mao Y(2017)Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers JAMA 317 2402-2416

[5] Malone KE(2023)Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 J Clin Oncol 41 1703-1737

[6] Begg CB(2018)CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study Breast Cancer Res 20 149-848

[7] Haile RW(2011)Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study Breast Cancer Res 13 R114-34

[8] Borg A(2017)Association of common genetic variants with contralateral breast cancer risk in the WECARE study J Natl Cancer Inst 109 10-214

[9] Concannon P(2021)The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant Genet Med 23 1726-1300

[10] Tellhed L(2020)Breast cancer polygenic risk score and contralateral breast cancer risk Am J Hum Genet 107 837-845

[1] Chen Y(1999)Epidemiology of contralateral breast cancer Cancer Epidemiol Biomark Prev 8 855-861

[2] Thompson W(2010)Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2 J Clin Oncol 28 2404-2410

[3] Semenciw R(2023)The impact of coding germline variants on contralateral breast cancer risk and survival Am J Hum Genet 110 475-486

[4] Mao Y(2017)Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers JAMA 317 2402-2416

[5] Malone KE(2023)Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 J Clin Oncol 41 1703-1737

[6] Begg CB(2018)CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study Breast Cancer Res 20 149-848

[7] Haile RW(2011)Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study Breast Cancer Res 13 R114-34

[8] Borg A(2017)Association of common genetic variants with contralateral breast cancer risk in the WECARE study J Natl Cancer Inst 109 10-214

[9] Concannon P(2021)The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant Genet Med 23 1726-1300

[10] Tellhed L(2020)Breast cancer polygenic risk score and contralateral breast cancer risk Am J Hum Genet 107 837-845